IMR Press / EJGO / Volume 25 / Issue 4 / pii/2004203

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma

Show Less
1 Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Cancer Research Center, Ben-Gurion University of the Negev, Beer-Sheva (Israel)
Eur. J. Gynaecol. Oncol. 2004, 25(4), 449–452;
Published: 10 August 2004
Abstract

Purpose of investigation: To report the experience of a single institution in the south of Israel with gemcitabine in heavily pre­treated patients with platinum-resistant recurrent ovarian, peritoneal and fallopian tube carcinoma. Methods: The hospital records of 21 patients with ovarian, peritoneal and fallopian tube carcinoma who had salvage chemother­apy with gemcitabine between October 1998 and November 2003 were retrospectively reviewed. Gemcitabine, 1000 mg/m2, was given on days 1, 8, and 15 of every 28 days. Dose intensity and relative dose intensity of gemcitabine were calculated. Response was determined using clinical evaluation, radiological reports and CA-125 level. Toxicity was graded using the National Cancer Institute (NCI) criteria. Results: The median relative dose intensity of gemcitabine received by the patients was 0.91, with 17 (81%) patients receiving more than 80% of the planned standard dose intensity. Two (9.5%) patients had complete response of disease lasting for ten and 33 months, respectively, eight (38.1%) had stable disease and 11 (52.4%) had progressive disease. Three (14.3%) patients had CA-125 complete response, five (23.8%) had CA-125 partial response, six (28.5%) had CA-125 stable levels and seven (33.3%) had CA-125 progressive levels. Toxicity was mainly hematological with grade 3-4 toxicity as follows: leukopenia - two (9.5%) patients, neutropenia - four (19%), thrombocytopenia - three (14.3%) and anemia - one (4.7%). Conclusion: Gemcitabine has some activity and low and well tolerated toxicity in heavily pretreated patients with platinum-resis­tant recurrent ovarian, peritoneal and fallopian tube carcinoma.

Keywords
Ovarian carcinoma
Chemotherapy
Gemcitabine
CA-125
Toxicity
Share
Back to top